CureVac is using the same messenger RNA approach that Moderna uses. Why is Moderna getting all the headlines?
News & Analysis: CureVac
There's little doubt that COVID-19 vaccines will save many lives, but that doesn't mean investors will be rewarded.
In the race for a vaccine, a pause in progress sets you back.
These companies made an early splash, but that doesn't mean they're a safe choice for investors.
Are any of these stocks good bets for other investors?
These two stocks have made shareholders rich in a very short amount of time. Here's why new potential investors should stay away.
BioNTech and CureVac will use the new funding to advance COVID-19 research and development in Germany.
Investors should exercise caution before buying into these high-flying growth stocks.
Late to the rally in coronavirus vaccine stocks? Consider these four rising biotechs.
That money will also be used for its production.